Stock 603739 QINGDAO VLAND BIOTECH INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Qingdao Vland Biotech INC.

Equities

603739

CNE100003GX8

Biotechnology & Medical Research

End-of-day quote Shanghai S.E.
Other stock markets
 23:00:00 05/05/2024 BST 		5-day change 1st Jan Change
15.26 CNY +10.02% Intraday chart for Qingdao Vland Biotech INC. +33.16% +0.26%
04-25 Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-25 Qingdao Vland Biotech INC. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 3,474 4,689 3,387 3,851 3,861 - -
Enterprise Value (EV) 1 3,474 4,689 3,387 3,851 3,861 3,861 3,861
P/E ratio 22.9 x 34.4 x 49.7 x 47.6 x 41.8 x 32.2 x 35.5 x
Yield - 0.86% 0.75% 0.66% 1.31% 1.34% 1.51%
Capitalization / Revenue 3.62 x 4.07 x 2.91 x 3.21 x 2.99 x 2.65 x 2.56 x
EV / Revenue 3.62 x 4.07 x 2.91 x 3.21 x 2.99 x 2.65 x 2.56 x
EV / EBITDA - - - 19.5 x 15.8 x 14.1 x 12.6 x
EV / FCF - -11.6 x -13.7 x - 22.1 x 50.1 x 23.4 x
FCF Yield - -8.62% -7.28% - 4.53% 1.99% 4.27%
Price to Book - 2.92 x 2.06 x 2.25 x 2.2 x 2.11 x 2.08 x
Nbr of stocks (in thousands) 216,534 252,085 252,412 253,029 253,029 - -
Reference price 2 16.04 18.60 13.42 15.22 15.26 15.26 15.26
Announcement Date 20/04/21 19/04/22 26/04/23 25/04/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 960.2 1,151 1,163 1,199 1,290 1,457 1,511
EBITDA 1 - - - 197.2 245 274 307
EBIT 1 - 170.9 102.9 122.9 139.5 173 166.5
Operating Margin - 14.85% 8.85% 10.25% 10.81% 11.88% 11.02%
Earnings before Tax (EBT) 1 - 171.4 102.2 122.5 139 172.7 166
Net income 1 - 132.6 69.84 80.71 91 119.7 109
Net margin - 11.52% 6% 6.73% 7.05% 8.22% 7.21%
EPS 2 0.7000 0.5400 0.2700 0.3200 0.3650 0.4733 0.4300
Free Cash Flow 1 - -404 -246.6 - 175 77 165
FCF margin - -35.1% -21.2% - 13.57% 5.29% 10.92%
FCF Conversion (EBITDA) - - - - 71.43% 28.1% 53.75%
FCF Conversion (Net income) - - - - 192.31% 64.35% 151.38%
Dividend per Share 2 - 0.1600 0.1000 0.1000 0.2000 0.2050 0.2300
Announcement Date 20/04/21 19/04/22 26/04/23 25/04/24 - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - -
Net Cash position - - - - - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 - -404 -247 - 175 77 165
ROE (net income / shareholders' equity) - 9.42% 4.3% 4.82% 5.24% 6.27% 5.86%
ROA (Net income/ Total Assets) - - - - 2.95% 2.96% 3.01%
Assets 1 - - - - 3,085 4,043 3,621
Book Value Per Share 2 - 6.370 6.520 6.750 6.930 7.250 7.330
Cash Flow per Share 2 - - 0.3800 0.6100 0.7600 0.9000 1.010
Capex 1 - 493 342 215 256 208 251
Capex / Sales - 42.88% 29.4% 17.91% 19.81% 14.3% 16.58%
Announcement Date 20/04/21 19/04/22 26/04/23 25/04/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Qingdao Vland Biotech INC.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
15.26
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
QINGDAO VLAND BIOTECH INC. Stock Qingdao Vland Biotech INC.
+0.26% 485M
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+9.15% 105B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.08% 104B
ARGENX SE Stock argenx SE
+5.79% 22.94B
BIONTECH SE Stock BioNTech SE
-11.55% 22.34B
GENMAB A/S Stock Genmab A/S
-7.01% 19.25B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-37.08% 17.08B
BEIGENE, LTD. Stock BeiGene, Ltd.
-9.91% 16.96B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.55% 14.16B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+40.04% 12.63B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 603739 Stock
  4. Financials Qingdao Vland Biotech INC.